• N6-Methyl-dATP: Advancing Epigenetic Fidelity Studies in AML

  2026-05-01

  N6-Methyl-dATP empowers high-precision research into DNA replication fidelity and methylation-driven gene regulation, directly accelerating advances in acute myeloid leukemia (AML) and antiviral strategy development. With APExBIO's rigorously validated solution, researchers gain workflow control and reproducibility, driving mechanistic discoveries and translational breakthroughs.

• Tioconazole: Precision Antifungal Strategies & Assay Design

  2026-04-30

  Explore Tioconazole’s role as an antifungal medication, delving into its advanced mechanisms and how innovative genomic findings shape high-fidelity assay development. This article offers a uniquely actionable, research-driven perspective for scientists seeking robust experimental outcomes.

• I-BET151 (GSK1210151A): Technical Guidance for BET Inhibitio

  2026-04-30

  I-BET151 (GSK1210151A) is a selective BET bromodomain inhibitor for precise modulation of epigenetic mechanisms in cancer biology research. This compound is optimized for use in apoptosis and cell cycle arrest assays, especially in models such as MLL-fusion leukemia. It is not intended for diagnostic or therapeutic applications and requires careful attention to solubility and handling to ensure reproducible results.

• CYR61 via Migrasomes Restores Osteogenic Function in Irradia

  2026-04-29

  This study reveals that the extracellular matrix protein CYR61, delivered by migrasomes, promotes both migration and osteoblastic differentiation in irradiated bone marrow mesenchymal stem cells (BMSCs). The findings provide mechanistic insights into bone regeneration after radiation damage and highlight potential therapeutic strategies for osteoradionecrosis of the jaw (ORNJ).

• GRA12: A Conserved Virulence Factor in Toxoplasma gondii Rev

  2026-04-29

  This study used systematic in vivo CRISPR-Cas9 screening to identify GRA12 as a secreted effector essential for Toxoplasma gondii virulence across diverse parasite strains and mouse hosts. GRA12's role in immune evasion and host-pathogen interactions advances understanding of conserved mechanisms of parasite persistence, with broad implications for targeting such pathways in infectious disease models.

• Reliable Angiokinase Inhibition: Nintedanib (BIBF 1120) in C

  2026-04-28

  This article delivers scenario-driven insights for reproducible cell viability and cytotoxicity workflows using Nintedanib (BIBF 1120), SKU A8252. Drawing on peer-reviewed evidence and validated protocols, we address protocol optimization, data interpretation, and vendor selection—empowering biomedical researchers to achieve robust antiangiogenic and antifibrotic results.

• AZ505: Scenario-Driven Solutions with a Potent SMYD2 Inhibit

  2026-04-28

  Discover how AZ505, a potent and selective SMYD2 inhibitor (SKU B1255), addresses core laboratory challenges in epigenetic and cancer biology research. This article combines scenario-driven Q&A, quantitative data, and validated protocols to guide researchers seeking reliable SMYD2 inhibition and reproducible results.

• HyperFluor 488 Goat Anti-Mouse IgG: Precision in Immunofluor

  2026-04-27

  The HyperFluor 488 Goat Anti-Mouse IgG antibody delivers high-sensitivity, low-background detection for advanced immunofluorescence and flow cytometry. Its superior signal amplification and workflow flexibility empower researchers tackling neuroepigenetic mechanisms and complex protein assays.

• Tacalcitol Monohydrate: Bridging Mechanism and Translation

  2026-04-27

  This thought-leadership article explores the unique mechanistic and translational opportunities of Tacalcitol monohydrate as a synthetic analog of vitamin D3. Integrating mechanistic insight, protocol guidance, and competitive positioning, the piece equips translational researchers to strategically leverage this compound in dermatological and oncological workflows, while providing evidence-based context and a forward-looking vision.

• JC-1 in Action: Optimizing Mitochondrial Membrane Potential

  2026-04-26

  JC-1 stands out as a gold-standard probe for mitochondrial membrane potential, enabling precise apoptosis and bioenergetics studies in cancer and beyond. This article delivers actionable workflows, troubleshooting, and evidence-driven enhancements for reliable results—showcasing how APExBIO’s JC-1 empowers advanced cellular research.

• Cisplatin (CDDP): Optimized Workflows for Cancer Research As

  2026-04-25

  Cisplatin (CDDP) serves as a gold-standard DNA crosslinking agent in apoptosis and chemoresistance research, but recent insights reveal its expanded role in inducing pyroptosis. This guide unpacks protocol refinements, troubleshooting strategies, and experimental innovations—enabling researchers to unlock new mechanistic layers in cancer research using APExBIO's high-purity Cisplatin.

• Fumagillin: Applied Workflows for Methionine Aminopeptidase-

  2026-04-24

  Fumagillin offers targeted inhibition of methionine aminopeptidase-2, enabling reproducible angiogenesis and parasitology assays in cancer and aquaculture research. This guide translates reference-driven insights into actionable protocols, troubleshooting recommendations, and advanced applications, leveraging the robust reliability of APExBIO’s supply.

• Luminescent ATP Cell Viability Assay I: Precision for Ferrop

  2026-04-24

  Explore the Luminescent ATP Cell Viability Assay Kit I for advanced cell viability measurement and luciferase luminescence detection, with novel insights into ferroptosis modulation. This article delivers a scientific perspective on assay selection for mitochondrial stress and regulated cell death research.

• TP53, ATM, and MDM2 Modulate Calicheamicin ADC Sensitivity i

  2026-04-23

  This study identifies TP53, ATM, and MDM2 as crucial determinants of acute leukemia cell sensitivity to calicheamicin-based antibody–drug conjugates (ADCs) through a genome-wide CRISPR/Cas9 approach. The findings clarify resistance mechanisms and suggest new combination strategies to enhance ADC efficacy.

• Acacetin in Duhuo Jisheng Decoction Inhibits IVDD via MAPK1/

  2026-04-23

  This study demonstrates that Duhuo Jisheng decoction (DHJS) alleviates intervertebral disc degeneration (IVDD) by inhibiting pyroptosis in nucleus pulposus cells via the acacetin-mediated MAPK1/HMOX1 pathway. These findings reveal a novel regulatory mechanism linking mitophagy and pyroptosis in IVDD, providing new insights for therapeutic intervention and research methodology.

456 records 20/31 page Previous Next First page 上5页 1617181920 下5页 Last page